Close Menu

NEW YORK – Liquid biopsy startup OncoCell MDx announced today that it has raised $22.2 million in a Series B financing round.

Royal Oak, Michigan-based OncoCell MDx will use the funding to support development and commercialization of its pan-disease diagnostic testing platform. The firm anticipates launching a blood test for detecting and grading aggressive prostate cancer next year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new study catalogues the genome and evolutionary history of the oak family, UPI reports.

Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.

A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.

In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.